What is Global Opioid-Induced Constipation Market?
The Global Opioid-Induced Constipation Market is a specialized and in-depth study of the pharmaceutical industry with a special focus on the global market trend analysis. Opioid-Induced Constipation (OIC) is a common side effect experienced by patients receiving opioid treatments. Opioids offer potent pain relief, however, they also interact with the nervous system in the gut, slowing down the body's digestive processes and often leading to constipation. This market revolves around the development, production, and distribution of drugs that can alleviate these symptoms and improve the quality of life for patients on opioid therapy. The market is driven by the increasing prevalence of diseases requiring opioid treatment and the growing geriatric population globally. However, the high cost of drugs and lack of awareness about OIC in developing countries may hinder the market growth. The market is expected to grow from US$ 2531 million in 2022 to US$ 3480.4 million by 2029, at a Compound Annual Growth Rate (CAGR) of 4.6% from 2023 to 2029.
Methylnaltrexone Bromide, Lubiprostone, Naloxegol, Others in the Global Opioid-Induced Constipation Market:
The Global Opioid-Induced Constipation Market is segmented based on the type of drugs used to treat the condition, which includes Methylnaltrexone Bromide, Lubiprostone, Naloxegol, and others. Methylnaltrexone Bromide is a peripherally acting mu-opioid receptor antagonist that is used to treat OIC in adults with chronic non-cancer pain. Lubiprostone is another drug used for the treatment of OIC. It increases the secretion of chloride ions in the intestines, which in turn increases the amount of water in the gut and helps to soften the stool. Naloxegol is an opioid antagonist used for the treatment of OIC in adult patients with chronic non-cancer pain. Other drugs in the market include those that are currently under research and development or are less commonly used. Among these, Lubiprostone is the largest segment, holding a share of about 5% in the global market.
Hospital, Pharmacy, Other in the Global Opioid-Induced Constipation Market:
The Global Opioid-Induced Constipation Market finds its applications in various areas including hospitals, pharmacies, and others. Hospitals are the primary care centers where patients receive opioid treatment and hence, are the major consumers of OIC drugs. Pharmacies, both online and offline, are the primary distribution channels for OIC drugs. They play a crucial role in making these drugs accessible to patients. Other areas of application include home healthcare, nursing homes, and long-term care centers. The demand for OIC drugs in these areas is driven by the increasing number of patients requiring opioid therapy and the growing awareness about OIC and its treatment options.
Global Opioid-Induced Constipation Market Outlook:
The global Opioid-Induced Constipation market has shown significant growth and is expected to continue this trend in the coming years. As per the recent market outlook, the market was valued at US$ 2531 million in 2022. It is projected to reach a value of US$ 3480.4 million by 2029, growing at a CAGR of 4.6% during the forecast period of 2023-2029. This growth can be attributed to the increasing prevalence of diseases requiring opioid treatment and the growing geriatric population. The market is dominated by the top three manufacturers who hold a share of over 45%. In terms of product type, Lubiprostone is the largest segment, accounting for about 5% of the market share.
| Report Metric | Details |
| Report Name | Opioid-Induced Constipation Market |
| Accounted market size in 2022 | US$ 2531 in million |
| Forecasted market size in 2029 | US$ 3480.4 million |
| CAGR | 4.6% |
| Base Year | 2022 |
| Forecasted years | 2023 - 2029 |
| Segment by Type |
|
| Segment by Application |
|
| Consumption by Region |
|
| By Company | Takeda Pharmaceuticals, Bayer, Sanofi, Mallinckrodt, Salix (Bausch Health), AstraZeneca, Progenics Pharmaceuticals, Purdue Pharm, Nektar Therapeutics, Daiichi Sankyo, Prestige, GSK, Shionogi |
| Forecast units | USD million in value |
| Report coverage | Revenue and volume forecast, company share, competitive landscape, growth factors and trends |
